CA2855660C - Therapeutic agent for arthrosis - Google Patents
Therapeutic agent for arthrosis Download PDFInfo
- Publication number
- CA2855660C CA2855660C CA2855660A CA2855660A CA2855660C CA 2855660 C CA2855660 C CA 2855660C CA 2855660 A CA2855660 A CA 2855660A CA 2855660 A CA2855660 A CA 2855660A CA 2855660 C CA2855660 C CA 2855660C
- Authority
- CA
- Canada
- Prior art keywords
- group
- arthrosis
- carbon atoms
- linear
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-247047 | 2011-11-11 | ||
| JP2011247047 | 2011-11-11 | ||
| PCT/JP2012/076478 WO2013069404A1 (ja) | 2011-11-11 | 2012-10-12 | 関節症治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2855660A1 CA2855660A1 (en) | 2013-05-16 |
| CA2855660C true CA2855660C (en) | 2019-04-16 |
Family
ID=48289788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2855660A Active CA2855660C (en) | 2011-11-11 | 2012-10-12 | Therapeutic agent for arthrosis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9085593B2 (https=) |
| EP (1) | EP2803359B1 (https=) |
| JP (1) | JP5465815B2 (https=) |
| KR (1) | KR101953181B1 (https=) |
| CN (1) | CN103906519B (https=) |
| AU (1) | AU2012337087B2 (https=) |
| BR (1) | BR112014011315B8 (https=) |
| CA (1) | CA2855660C (https=) |
| ES (1) | ES2634008T3 (https=) |
| IN (1) | IN2014CN04222A (https=) |
| MY (1) | MY168931A (https=) |
| PH (1) | PH12014501058B1 (https=) |
| RU (1) | RU2646457C2 (https=) |
| SG (1) | SG11201402226PA (https=) |
| WO (1) | WO2013069404A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3483169B1 (en) | 2014-08-12 | 2021-05-26 | Otsuka Chemical Co., Ltd. | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same |
| JP6727596B1 (ja) | 2019-11-22 | 2020-07-22 | 国立大学法人お茶の水女子大学 | カルバリゾホスファチジン酸 |
| JP7566783B2 (ja) | 2019-12-23 | 2024-10-15 | 大塚化学株式会社 | カルバ環状ホスファチジン酸化合物 |
| JP7736256B2 (ja) * | 2020-11-13 | 2025-09-09 | 株式会社マツモト交商 | 環状ホスファチジン酸含有組成物及び美容方法 |
| CN116710105A (zh) * | 2020-11-26 | 2023-09-05 | 山椒株式会社 | 肺纤维化治疗剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2700350B2 (ja) | 1990-04-20 | 1998-01-21 | 小糸工業株式会社 | 車両感知器 |
| JP3195833B2 (ja) | 1991-09-30 | 2001-08-06 | きみ子 室伏 | 新規生理活性物質及びその製造法 |
| JPH07149772A (ja) | 1993-11-26 | 1995-06-13 | Sagami Chem Res Center | タンパク質リン酸化酵素ｃの活性促進剤 |
| JPH07258278A (ja) | 1994-03-18 | 1995-10-09 | Sagami Chem Res Center | １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤 |
| JPH0925235A (ja) | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤 |
| JP2001178489A (ja) | 1999-12-24 | 2001-07-03 | Kimiko Murofushi | 環状ホスファチジン酸の製造法 |
| JP4815063B2 (ja) * | 2001-04-13 | 2011-11-16 | きみ子 室伏 | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤 |
| JP4836345B2 (ja) * | 2001-04-13 | 2011-12-14 | きみ子 室伏 | 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤 |
| US20040214799A1 (en) * | 2001-05-21 | 2004-10-28 | Mutsuko Mukai | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives |
| JP4162927B2 (ja) | 2002-06-11 | 2008-10-08 | きみ子 室伏 | カルバ環状ホスファチジン酸誘導体 |
| RU2240131C1 (ru) * | 2003-04-04 | 2004-11-20 | Аладьев Сергей Иванович | Средство "артровит" для профилактики и лечения артритов и артрозов |
| CA2521189A1 (en) * | 2003-04-11 | 2004-10-28 | Gabor Tigyi | Lysophosphatidic acid analogs and inhibition of neointima formation |
| JP4873352B2 (ja) | 2005-02-16 | 2012-02-08 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン |
| EP2098237B1 (en) * | 2006-12-28 | 2012-08-29 | Ochanomizu University | Analgesic agent comprising cyclic phosphatidic acid derivative |
| JP2010189315A (ja) * | 2009-02-18 | 2010-09-02 | Unitika Ltd | 関節軟骨損傷治癒促進剤及びそれを含有する飲食品 |
-
2012
- 2012-10-12 JP JP2013542900A patent/JP5465815B2/ja active Active
- 2012-10-12 MY MYPI2014701211A patent/MY168931A/en unknown
- 2012-10-12 PH PH1/2014/501058A patent/PH12014501058B1/en unknown
- 2012-10-12 IN IN4222CHN2014 patent/IN2014CN04222A/en unknown
- 2012-10-12 AU AU2012337087A patent/AU2012337087B2/en active Active
- 2012-10-12 RU RU2014123690A patent/RU2646457C2/ru active
- 2012-10-12 BR BR112014011315A patent/BR112014011315B8/pt active IP Right Grant
- 2012-10-12 SG SG11201402226PA patent/SG11201402226PA/en unknown
- 2012-10-12 WO PCT/JP2012/076478 patent/WO2013069404A1/ja not_active Ceased
- 2012-10-12 ES ES12847890.6T patent/ES2634008T3/es active Active
- 2012-10-12 US US14/357,089 patent/US9085593B2/en active Active
- 2012-10-12 CN CN201280055135.7A patent/CN103906519B/zh active Active
- 2012-10-12 EP EP12847890.6A patent/EP2803359B1/en active Active
- 2012-10-12 KR KR1020147015608A patent/KR101953181B1/ko active Active
- 2012-10-12 CA CA2855660A patent/CA2855660C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103906519A (zh) | 2014-07-02 |
| BR112014011315A2 (pt) | 2017-05-09 |
| AU2012337087A1 (en) | 2014-06-05 |
| EP2803359A4 (en) | 2015-12-16 |
| BR112014011315B8 (pt) | 2020-09-15 |
| PH12014501058A1 (en) | 2014-06-23 |
| EP2803359B1 (en) | 2017-04-19 |
| NZ624870A (en) | 2016-01-29 |
| US20140309194A1 (en) | 2014-10-16 |
| HK1199406A1 (en) | 2015-07-03 |
| RU2646457C2 (ru) | 2018-03-05 |
| CN103906519B (zh) | 2017-10-10 |
| BR112014011315B1 (pt) | 2020-03-03 |
| IN2014CN04222A (https=) | 2015-07-17 |
| RU2014123690A (ru) | 2015-12-20 |
| EP2803359A1 (en) | 2014-11-19 |
| SG11201402226PA (en) | 2014-10-30 |
| US9085593B2 (en) | 2015-07-21 |
| JPWO2013069404A1 (ja) | 2015-04-02 |
| AU2012337087B2 (en) | 2016-11-17 |
| WO2013069404A1 (ja) | 2013-05-16 |
| CA2855660A1 (en) | 2013-05-16 |
| MY168931A (en) | 2019-01-09 |
| ES2634008T3 (es) | 2017-09-26 |
| KR20140098778A (ko) | 2014-08-08 |
| KR101953181B1 (ko) | 2019-02-28 |
| PH12014501058B1 (en) | 2019-11-08 |
| JP5465815B2 (ja) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2855660C (en) | Therapeutic agent for arthrosis | |
| Russell et al. | Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas | |
| BG66037B1 (bg) | Пролекарства на фосфонат нуклеотидни аналози и методи за тяхното селектиране и получаване | |
| Breiser et al. | Distribution and metabolism of hexadecylphosphocholine in mice | |
| JPH09511493A (ja) | デキサナビノール誘導体及び同誘導体の神経保護薬剤組成物としての利用 | |
| CN112437667B (zh) | 细胞保护方法和组合物 | |
| EP3305795A1 (en) | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof | |
| US8017597B2 (en) | Analgesic agent comprising cyclic phosphatidic acid derivative | |
| JP6864899B2 (ja) | 損傷治療剤 | |
| EP4049724A1 (en) | Pharmaceutical composition for protecting cartilage | |
| NZ624870B2 (en) | Therapeutic agent for arthrosis | |
| HK1199406B (en) | Therapeutic agent for joint diseases | |
| BR112012022349B1 (pt) | Composto, método para tratar uma doença, e, processo | |
| JPH02256610A (ja) | ポリアロマティック化合物を含有する医薬用組成物 | |
| EP0893123A1 (en) | Agent for use in the prevention and treatment of disorders associated with various types of ageing | |
| US20090104280A1 (en) | Pharmaceutical compositions for treating/preventing motor organ diseases | |
| Hasegawa et al. | Structure and pulmonary toxicity relationship on O, O‐dimethyl S‐alkyl phosphorothioate esters | |
| Betbeder et al. | Anti-trypanosomal compounds. I. In vivo and in vitro activity of inhibitors of glycolysis in trypanosomes | |
| JP2020515633A (ja) | ヘパラン硫酸糖模倣物化合物並びにその医薬品及び薬用化粧品としての使用 | |
| WO2024210211A1 (ja) | アルツハイマー型認知症を中心とする認知症の改善・治療薬 | |
| Chavez | Practicum three. A new route to macrocyclic-based phosphonate acyloxymethyl esters: Synthesis, cell and heart loading, and (31) P NMR. Practicum two. Characterization of the low molecular weight fraction (LMWF) of an aloe vera extract. Practicum one. Synthesis of preorganized polyether macrocycles for Li (+) recognition | |
| CN110655534A (zh) | 替诺福韦脂质单酯化合物及其制备方法和应用 | |
| Nikolewski | The Effect of Cyclophosphamide (Cytoxan) on the Bladder Mucosa | |
| Geelen et al. | The effect of subtoxic doses of verocytotoxin on endothelial cells | |
| WO2008017586A2 (de) | Spezielle carbonylbisimino-verbindungen zur behandlung von immunerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170518 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |